<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric unipolar depression and pharmacotherapy: Choosing a medication</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric unipolar depression and pharmacotherapy: Choosing a medication</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pediatric unipolar depression and pharmacotherapy: Choosing a medication</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Scott Moreland, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Liza Bonin, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There have been several phases of pharmacotherapy studies for unipolar depression in children and adolescents [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial studies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic antidepressant phase</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Second-generation antidepressant phase, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The era of the US Food and Drug Administration boxed warning about antidepressants and suicidal ideation and behavior (see  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>)</p><p></p><p>The initial studies that investigated pharmacotherapy for pediatric depression occurred in the 1960s and were limited by several problems (eg, mixed diagnostic groups and different outcome measures across studies). Nonetheless, these studies established that properly monitored patients could safely tolerate antidepressants, which was necessary for conducting the randomized trials that ushered in the subsequent eras.</p><p>This topic reviews the choice of acute pharmacotherapy for children and adolescents with depressive disorders and the use of continuation and maintenance treatment, as well as the indications and efficacy of selective SSRIs, SNRIs, tricyclic antidepressants, and other antidepressants in depressed youth. Separate topics discuss the general principles for prescribing pharmacotherapy for pediatric depression, the effect of antidepressant medications on suicide risk in children and adolescents, psychosocial treatments for adolescent depression, an overview of treating pediatric depression, and the pharmacology, administration, and side effects of antidepressants in adults.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/88735.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: General principles"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1228.html" rel="external">"Pediatric unipolar depression: Psychotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86265.html" rel="external">"Serotonin modulators: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/85816.html" rel="external">"Atypical antidepressants: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="headingAnchor" id="H359879"><span class="h1">CHOICE OF MEDICATION FOR ACUTE TREATMENT</span><span class="headingEndMark"> — </span>Decisions about using pharmacotherapy in pediatric depression must be individualized after discussing the benefits and risks with patients and families. Additional information about choosing a treatment regimen is discussed separately. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression", section on 'Choice of therapy'</a>.)</p><p class="headingAnchor" id="H359886"><span class="h2">First-line</span><span class="headingEndMark"> — </span>For children and adolescents with acute depressive disorders, first-line pharmacotherapy is <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> [<a href="#rid2">2</a>]. There is more consistent, high-quality evidence for the efficacy of fluoxetine than other antidepressants [<a href="#rid3">3,4</a>]. The efficacy of fluoxetine is discussed elsewhere in this topic. (See <a class="local">'Fluoxetine'</a> below.)</p><p>Choosing an antidepressant other than <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> as first-line treatment may be reasonable for reasons that include:</p><p class="bulletIndent1"><span class="glyph">●</span>Desire to avoid specific adverse effects  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Response to a different antidepressant during a prior depressive episode</p><p class="bulletIndent1"><span class="glyph">●</span>Response to a different antidepressant by parent or sibling</p><p class="bulletIndent1"><span class="glyph">●</span>Known hypersensitivity to <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> in the patient or family</p><p class="bulletIndent1"><span class="glyph">●</span>Patient and/or family preference</p><p class="bulletIndent1"><span class="glyph">●</span>Potential drug-drug interactions</p><p></p><p>Specific interactions of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p class="headingAnchor" id="H359893"><span class="h2">Second-line</span><span class="headingEndMark"> — </span>Acute pediatric depressive episodes do not remit with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> in approximately 30 percent of patients [<a href="#rid3">3</a>]. For these treatment-resistant patients, we suggest <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> [<a href="#rid2">2</a>]; however, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> or <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> are reasonable choices, based upon their efficacy in randomized trials [<a href="#rid5">5</a>]. Another reasonable alternative is <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, which appears to be comparable to selective serotonin reuptake inhibitors (SSRIs) in treatment-resistant patients [<a href="#rid6">6</a>]. We typically do not use <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> for pediatric depression because of its lack of demonstrated efficacy [<a href="#rid5">5,7</a>]. The efficacy of sertraline, escitalopram, citalopram, venlafaxine, and paroxetine is discussed elsewhere in this topic. (See <a class="local">'Other specific SSRIs'</a> below and <a class="local">'Indications and efficacy'</a> below.)</p><p class="headingAnchor" id="H74941195"><span class="h2">Third-line</span><span class="headingEndMark"> — </span>When third-line therapy is necessary for pediatric depression, we recommend consultation with or referral to a child and adolescent psychiatrist.</p><p>For children and adolescents with acute depressive disorders who do not respond to <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> as well as a second trial with a different SSRI and a third trial with <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, we suggest <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> or <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, based upon randomized trials in adults and low-quality studies in youth. The evidence supporting the use of these medications is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Antidepressants'</a> and <a class="local">'Other antidepressants'</a> below.)</p><p class="headingAnchor" id="H159491114"><span class="h1">CONTINUATION AND MAINTENANCE TREATMENT</span><span class="headingEndMark"> — </span>Based upon randomized trials, children and adolescents with unipolar major depression who remit with pharmacotherapy should continue the same regimen for at least another 6 to 12 months [<a href="#rid8">8</a>]. Relapse frequently occurs in pediatric patients who stop their antidepressants soon after their depressive syndromes improve [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a>.)</p><p>Evidence for the efficacy of continuation and maintenance pharmacotherapy includes a meta-analysis of three randomized trials (164 children and adolescents with unipolar major depression who remitted with treatment) that compared pharmacotherapy (<a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> or <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>) with placebo for 24 to 52 weeks [<a href="#rid12">12</a>]. Relapse was less likely in patients who received medications than placebo (odds ratio 0.3, 95% CI 0.2-0.6). In the biggest trial (n = 102), relapse occurred in fewer patients who received fluoxetine than placebo (42 versus 69 percent) [<a href="#rid13">13</a>]. In addition, randomized trials in depressed adults who remitted with antidepressants have established that recurrence is less frequent in patients who continue and maintain pharmacotherapy. (See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment", section on 'Antidepressant medications'</a>.)</p><p>Based upon adult studies and clinical experience with youth, maintenance pharmacotherapy beyond 6 to 12 months for children and adolescents is often indicated in the following situations [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The presenting depressive episode included:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psychotic features (eg, delusions or hallucination)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe suicidal ideation or behavior</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe functional impairment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment resistance</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A duration ≥2 years</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An unsuccessful prior attempt to taper the antidepressant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The course of illness includes three or more episodes of unipolar major depression</p><p></p><p>Maintenance studies extending beyond one year have not been conducted in youth, and thus the long-term effects of antidepressants on maturation and development in pediatric patients are unknown.</p><p class="headingAnchor" id="H109482070"><span class="h1">PSYCHOTIC DEPRESSION</span><span class="headingEndMark"> — </span>Pediatric patients with psychotic features (eg, delusions and hallucinations) are typically referred to mental health clinicians for evaluation and treatment. (See  <a class="medical medical_review" href="/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment"</a>.)</p><p class="headingAnchor" id="H109482217"><span class="h1">OVERVIEW OF EFFICACY</span><span class="headingEndMark"> — </span>For children and adolescents with depressive disorders, randomized trials have shown that antidepressants collectively are beneficial [<a href="#rid14">14-16</a>]. However, other analyses indicate that the efficacy of antidepressants varies among different classes. As an example, selective serotonin reuptake inhibitors (SSRIs) collectively have been found to be efficacious (see <a class="local">'Efficacy'</a> below), whereas tricyclic antidepressants often fail to demonstrate any benefit. (See <a class="local">'Efficacy'</a> below.)</p><p>In addition, within a single antidepressant class, the efficacy of individual antidepressants for childhood and adolescent depression may vary. One such example is the SSRIs; <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> has demonstrated efficacy in multiple meta-analyses of randomized trials, whereas the efficacy of <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> is less well established. However, no head to head trials have compared one SSRI with another. (See <a class="local">'Efficacy'</a> below.)</p><p>Outcomes in pharmacotherapy studies of depressed youth can vary because of methodologic issues. As an example, lower placebo response rates are more likely to occur in trials that are conducted at only a few sites (eg, 3) rather than many sites (eg, 10) [<a href="#rid17">17</a>]. In addition, it may be easier to demonstrate the benefits of antidepressants in studies that are conducted by experienced investigators at university settings with more severely ill patients.</p><p class="headingAnchor" id="H109482224"><span class="h2">All antidepressants</span><span class="headingEndMark"> — </span>Antidepressants as a class are efficacious for pediatric depressive disorders. A pooled analysis of 29 randomized trials (3069 patients, age ≤20 years, treated for a median of eight weeks) compared antidepressants (primarily SSRIs or tricyclics) with placebo, and found that response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received antidepressants than placebo (60 versus 49 percent) [<a href="#rid14">14</a>].</p><p>Although a network meta-analysis concluded that among 14 different antidepressants, only <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> was efficacious [<a href="#rid18">18</a>], we disagree with this conclusion. The study was rigorous and included 34 randomized trials with more than 5000 pediatric patients with acute major depression; nevertheless, the conclusion that only fluoxetine is effective is not justified for several reasons [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to the network meta-analysis, the investigators initially conducted standard meta-analyses of randomized trials to directly compare one drug with placebo or another active drug. The standard meta-analyses found that <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> were each superior to placebo. In addition, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> was superior to <a class="drug drug_general" data-topicid="9283" href="/d/drug information/9283.html" rel="external">clomipramine</a> (and fluoxetine was superior to <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Next, the authors performed a network meta-analysis using direct comparisons between two drugs or between a drug and placebo, as well as indirect comparisons of the drugs through their relative effect with a common comparator (typically placebo). The network meta-analysis found that for the primary outcome of improvement in depressive symptoms, only <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> was better than placebo; however, this may be due to the questionable assumption that variability (heterogeneity) was the same in each pairwise comparison. In addition, for the secondary outcome of response (reduction of baseline symptoms ≥50 percent), <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> and <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, as well as fluoxetine, were each superior to placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many patients who are treated with antidepressants have severe and chronic depressive symptoms; these patients may be more likely to respond to active drugs than placebo, but are nearly always excluded from clinical trials. In addition, the network meta-analysis excluded studies of patients with treatment-resistant patients (eg, patients who do not respond to initial treatment with psychotherapy).</p><p></p><p class="headingAnchor" id="H109482231"><span class="h3">Second-generation antidepressants</span><span class="headingEndMark"> — </span>Second-generation antidepressants include SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants (eg, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>), and serotonin modulators (eg, <a class="drug drug_general" data-topicid="16102" href="/d/drug information/16102.html" rel="external">vilazodone</a> and <a class="drug drug_general" data-topicid="91014" href="/d/drug information/91014.html" rel="external">vortioxetine</a>), which were developed after the first-generation of antidepressants (tricyclics and monoamine oxidase inhibitors). Based upon randomized trials, second-generation antidepressants collectively are effective for juvenile unipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 15 trials (n &gt;2900 patients) compared antidepressants (SSRIs or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) with placebo and found that remission or response occurred in more patients treated with antidepressants (risk ratio 1.2, 95% CI 1.1-1.3) [<a href="#rid5">5</a>]. In addition, antidepressants improved functioning, and subgroup analyses indicated that antidepressants were beneficial for both children (aged 6 to 12 years) and adolescents (aged 13 to 18 years). However, adverse effects occurred in more patients who received antidepressants than placebo (risk ratio 1.11, 95% CI 1.05-1.17).</p><p></p><p class="bulletIndent1">Subsequently, the same investigators conducted a network meta-analysis of 26 trials in youth aged 6 to 18 years (n &gt;6400), using direct comparisons between two drugs or between a drug and placebo, as well as indirect comparisons of the drugs through their relative effect with a common comparator such as placebo (conventional meta-analyses use only direct comparisons) [<a href="#rid4">4</a>]. The results suggested that most newer antidepressants may reduce depressive symptoms compared with placebo, and that among most antidepressants, there were small differences in the reduction of depressive symptoms. The investigators concluded that first-line options include <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, as well as <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, and <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of 13 randomized trials compared antidepressants (SSRIs, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) with placebo in 2910 children and adolescents treated for a median of eight weeks [<a href="#rid15">15</a>]. Response occurred in more patients treated with antidepressants than placebo (61 versus 50 percent). However, antidepressants appeared to be less efficacious for longer episodes of depression. In addition, subgroup analyses found that for adolescents (age ≥12 years), antidepressants were superior to placebo; in children (age &lt;12 years), there was a trend for a greater rate of response with antidepressants.</p><p></p><p>The risk of suicidal ideation and behavior with second-generation antidepressants are discussed separately. (See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents", section on 'Randomized trials'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SELECTIVE SEROTONIN REUPTAKE INHIBITORS</span><span class="headingEndMark"> — </span>The selective serotonin reuptake inhibitors (SSRIs) include [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a></p><p></p><p>The pharmacology of SSRIs (including their structure, pharmacodynamics, pharmacokinetics, and drug-drug interactions) is discussed separately. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Pharmacology'</a>.)</p><p class="headingAnchor" id="H100966611"><span class="h2">Indications</span><span class="headingEndMark"> — </span>SSRIs are indicated for children and adolescents with moderate to severe unipolar major depression  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 2</a>) as well as other depressive disorders accompanied by moderate to severe functional impairment. However, these drugs are generally not prescribed for patients who have subsyndromal depressive symptoms or mild depressive disorders.</p><p class="headingAnchor" id="H50853897"><span class="h2">Efficacy</span></p><p class="headingAnchor" id="H100966744"><span class="h3">SSRIs as a class</span><span class="headingEndMark"> — </span>SSRIs as a class are effective for pediatric depressive disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled analysis of 12 randomized trials (2220 patients with depressive disorders, age ≤20 years, treated for 7 to 12 weeks) that compared SSRIs (<a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>; two trials examined <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) with placebo, response (reduction of baseline symptoms ≥50 percent) occurred in more patients treated with SSRIs than placebo (59 versus 51 percent) [<a href="#rid14">14</a>]. Among the antidepressants, fluoxetine had the largest pooled efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SSRIs are more efficacious than tricyclics for pediatric depression. A meta-analysis of five randomized trials (422 depressed patients, mean age 15 years) compared SSRIs with tricyclics and found a significant, clinically moderate effect favoring SSRIs over tricyclics [<a href="#rid20">20</a>]. Heterogeneity across studies was moderate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 13 randomized trials compared SSRIs (<a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>) with placebo in children and adolescents with unipolar major depression (n &gt;3000); SSRIs were superior to placebo and most of the benefit accrued within the first four weeks of treatment [<a href="#rid21">21</a>]. Although the study found no advantage for one SSRI over the other SSRIs, the paucity of trials limited the statistical power to detect a difference.</p><p></p><p class="headingAnchor" id="H14"><span class="h3">Fluoxetine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> is efficacious for treating children and adolescents with unipolar major depression [<a href="#rid22">22-27</a>]. A meta-analysis of patient level data from four randomized trials (708 youths with major depression) lasting six weeks found that response occurred in more patients who received fluoxetine than placebo (30 versus 6 percent) [<a href="#rid3">3</a>]. Other meta-analyses have also demonstrated the efficacy of fluoxetine [<a href="#rid5">5,15,18</a>]. In addition, fluoxetine is effective for continuation treatment [<a href="#rid13">13,26</a>]. (See <a class="local">'Continuation and maintenance treatment'</a> above.)</p><p>However, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> can cause side effects in depressed youth. A meta-analysis of two randomized trials (440 patients) found that adverse events occurred in more patients who received fluoxetine than placebo (risk ratio 1.2, 95% CI 1.1-1.4) [<a href="#rid5">5</a>]. One trial found that abdominal pain, diarrhea, influenza, insomnia, sedation, sinusitis, or vomiting were among the most common complaints in patients who received fluoxetine during 12 weeks of treatment, and the incidence of each adverse event was at least two times greater among patients who received fluoxetine than placebo [<a href="#rid24">24</a>]. Nevertheless, the frequency of these adverse events in patients receiving fluoxetine was low, ranging from two to six percent of patients. Additional information about side effects is discussed elsewhere in this topic. (See <a class="local">'Adverse side effects'</a> below.)</p><p class="headingAnchor" id="H360425"><span class="h3">Other specific SSRIs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> is modestly efficacious for treating children and adolescents with depressive disorders, based upon randomized trials, and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> and <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> may also be effective. By contrast, evidence for the efficacy of <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> is lacking, and randomized trials with <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> have found no benefit [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sertraline</strong> – <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> appears to be efficacious for pediatric unipolar major depression. A pooled analysis of two similar, 10 week randomized trials compared sertraline (mean dose 131 mg per day) with placebo in 364 patients [<a href="#rid28">28</a>]. Response (reduction of baseline symptoms ≥40 percent) occurred in more patients who received sertraline than placebo (69 versus 59 percent). However, discontinuation of treatment due to side effects occurred in more patients treated with sertraline than placebo (9 versus 3 percent); adverse effects associated with sertraline included agitation, anorexia, diarrhea, and vomiting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Escitalopram</strong> – The benefit of <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> for children and adolescents with depressive disorders is modest, based upon two randomized trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An eight-week trial (n = 261 youth 6 to 17 years old) found that improvement of symptoms with <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> (mean dose 12 mg per day) and placebo was comparable [<a href="#rid29">29</a>]. However, a subgroup analysis in adolescents (age 12 to 17 years; n = 157) found that improvement of depressive symptoms was greater with escitalopram than placebo, consistent with results from one meta-analysis [<a href="#rid15">15</a>] discussed elsewhere in this topic. (See <a class="local">'Second-generation antidepressants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another-eight week trial compared <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> (mean dose 13 mg per day) with placebo in 311 patients and found that improvement was greater with escitalopram [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of the two trials (572 patients) found that there was a trend for a greater rate of response or remission with <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> than placebo (risk ratio 1.19, 95% CI 0.97-1.45) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Citalopram</strong> – <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> may be beneficial for children and adolescents with depressive disorders, but the results across randomized trials are inconsistent:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An eight-week trial compared <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (mean dose 24 mg per day) with placebo in 174 patients [<a href="#rid31">31</a>]. Complete or nearly complete resolution of symptoms occurred in more patients who received citalopram than placebo (36 versus 24 percent), and discontinuation of treatment due to side effects in both groups was 6 percent.</p><p></p><p class="bulletIndent2">A 12-week trial (n = 233) found that the rate of remission with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (mean dose 26 mg per day) and placebo was comparable (33 and 36 percent of patients) [<a href="#rid32">32</a>]. However, treatment was contaminated in that psychotherapy was allowed outside of the study protocol and administered to 69 percent of the patients. Among patients who did not receive psychotherapy (n = 65), remission occurred in more patients treated with citalopram than placebo (45 versus 19 percent).</p><p></p><p class="bulletIndent2">A meta-analysis of the two trials (407 patients) found that remission with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and placebo was comparable (risk ratio 1.2, 95% CI 0.7-1.9); heterogeneity across studies was moderate to large [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a third trial, adolescents who did not respond to initial treatment with an SSRI were assigned to switch to a different SSRI or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid6">6</a>]. Among those who switched to <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (n = 34) or <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> (n = 84), response was comparable for the two groups (56 and 49 percent).</p><p></p><p class="bulletIndent1">The US Food and Drug Administration issued warnings that <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends that the maximum dose should not exceed 40 mg per day [<a href="#rid33">33,34</a>]. We generally get an electrocardiogram for patients who are taking 20 or 30 mg per day and are considering a dose increase to 40 mg per day. Additional information about the cardiac effects of SSRIs is discussed separately. (See <a class="local">'Cardiac events'</a> below and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Cardiac'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluvoxamine</strong> – Although randomized trials have demonstrated the efficacy and safety of <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> for treating pediatric anxiety disorders [<a href="#rid35">35,36</a>], there are no high-quality studies in patients with depressive disorders </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paroxetine</strong> – <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> does not appear to help children and adolescents with depressive disorders. A meta-analysis of four randomized trials (704 patients) found that response or remission with paroxetine and placebo was comparable (risk ratio 1.1, 95% CI 0.9-1.4) [<a href="#rid5">5</a>].</p><p></p><p>Possible explanations for the lack of proven efficacy of some specific SSRIs for pediatric depressive disorders include the following [<a href="#rid5">5,37,38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The studies were performed quickly in response to the United States Food and Drug Administration's promise of exclusivity to manufacturers who conducted clinical trials of medications in children and adolescents. This may have contributed to suboptimal study design with smaller samples and shorter duration. Support for this hypothesis includes a finding that studies with more study sites had higher placebo response rates, suggesting that trials conducted quickly with a large number of sites may not have carefully screened for clinically significantly depressed patients, and thus enrolled youth with less severe illness [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">Increasing placebo response rates in pediatric patients with unipolar major depression decreases the ability to detect a statistically significant difference between active treatment and placebo [<a href="#rid17">17,39-42</a>]. Other factors associated with higher placebo effects include study sites with relatively low enrollment numbers, as well as studies that include a large number of clinic visits, which provide repeated contact with solicitous research assistants and other support staff. In addition, placebo response appears to be affected by the disorder studied, and is higher in pediatric major depression than in anxiety disorders and obsessive-compulsive disorder [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The controlled trials were not preceded by studies that established the most appropriate dose; there is evidence that metabolism of some SSRIs occurs more quickly in pediatric patients than adults [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be greater heterogeneity in response among children and adolescents than in adults, perhaps due to varying rates of maturation in the neural networks involved in depressive disorders.</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Adverse side effects</span><span class="headingEndMark"> — </span>The SSRIs are generally well tolerated with minimal adverse effects  (<a class="graphic graphic_table graphicRef63001" href="/d/graphic/63001.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 1</a>) that tend to be dose dependent. Most side effects subside over one to two weeks or with dose reduction [<a href="#rid8">8</a>]. The most common adverse effects include:</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation, jitteriness, or akathisia (restlessness and inability to sit still)</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep changes</p><p></p><p>Additional information about SSRI side effects is discussed separately. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p>The risk of patients with bipolar disorder switching from major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 4</a>) to hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 5</a>) or mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 6</a>) due to treatment with antidepressants is discussed separately. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Risk of switching to mania'</a>.)</p><p>SSRIs may inhibit hepatic cytochrome P450 enzymes that metabolize other medications, thereby causing drug-drug interactions. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'</a>.)</p><p>Specific interactions of SSRIs with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p>Observational studies have found associations between SSRIs and other adverse effects; however, in many instances, the low quality of the evidence leads us to suggest that clinicians should not change their practice with regard to prescribing SSRIs. As an example, a retrospective national registry study found that use of SSRIs among individuals aged 15 to 24 years was associated with convictions for violent criminal behavior [<a href="#rid44">44</a>]. Problems with the study include confounds (eg, symptom severity or alcohol abuse); reverse causality (ie, individuals may have been more likely to receive SSRIs when they were at greater risk of committing violent crimes); and the finding that low doses, but not moderate or higher doses, were associated with violent crime. The authors concluded that their study did not warrant changes in clinical practice.</p><p>Low-quality studies have also examined the association between exposure to SSRIs and side effects, such as decreased bone density and bleeding, including upper gastrointestinal bleeding, intraoperative bleeding, and stroke. (See  <a class="medical medical_review" href="/d/html/2036.html" rel="external">"Drugs that affect bone metabolism", section on 'Antidepressants'</a> and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H1590579002"><span class="h3">Activation</span><span class="headingEndMark"> — </span>Antidepressant-related behavioral activation is characterized by symptoms of disinhibition, restlessness, impulsivity, hyperactivity, irritability and insomnia [<a href="#rid45">45</a>]. The symptoms tend to occur together and frequently emerge early in treatment or following an increase in dose. The risk of activation appears to be greater in children than adolescents, as well as patients with rapidly increasing serum concentrations or relatively high concentrations. Symptoms resolve if the dose is decreased or the antidepressant is stopped. There appears to be a slight chance of recurrence with exposure to another antidepressant. </p><p class="headingAnchor" id="H33730822"><span class="h3">Cardiac events</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> may be associated with adverse cardiac events in pediatric patients, but these rarely occur. A retrospective study of insurance claims data (n &gt;100,000 patients, age &lt;18 years) examined the risk of ventricular arrhythmia, cardiac arrest, and sudden death within 12 months of starting an SSRI [<a href="#rid46">46</a>]. Analyses were adjusted for propensity to receive a specific SSRI and factors such as age, sex, psychiatric and general medical diagnoses, and other medications. Forty cardiac events occurred, and the estimated risk was greater with citalopram (adjusted hazard ratio 3.5, 95% CI 1.1-11.5) and escitalopram (adjusted hazard ratio 3.3, 95% CI 1.1-10.1) than <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>. By contrast, the risk with <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> or <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> was comparable to that of fluoxetine.</p><p>Additional information about SSRIs and cardiac side effects is discussed separately in the context of adults. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Cardiac'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Serotonin syndrome</span><span class="headingEndMark"> — </span>Serotonin syndrome is a potentially lethal condition caused by overstimulation of central and peripheral serotonin receptors. Clinical features include anxiety, agitation, delirium, diaphoresis, tachycardia, hypertension, hyperthermia, gastrointestinal distress, tremor, muscle rigidity, myoclonus, and hyperreflexia. It typically results from an interaction between multiple medications that increase serotonergic neurotransmission  (<a class="graphic graphic_table graphicRef64604" href="/d/graphic/64604.html" rel="external">table 7</a>). However, the syndrome can occur after initiating or increasing a single serotonergic drug. It is not known whether SSRIs differ in their likelihood to cause this syndrome. The epidemiology, clinical features, diagnosis, treatment, and prevention of serotonin syndrome are discussed separately. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Suicidality</span><span class="headingEndMark"> — </span>There is a potential for increased suicidal ideation and behavior in pediatric patients who initiate treatment with antidepressants or with dose increases or decreases. (See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p class="headingAnchor" id="H128735767"><span class="h3">Discontinuation (withdrawal) syndrome</span><span class="headingEndMark"> — </span>Abrupt discontinuation of SSRIs can cause withdrawal symptoms. (See  <a class="medical medical_review" href="/d/html/88735.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: General principles", section on 'Discontinuing pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS</span><span class="headingEndMark"> — </span>The serotonin-norepinephrine reuptake inhibitors (SNRIs) include <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, <a class="drug drug_general" data-topicid="8944" href="/d/drug information/8944.html" rel="external">desvenlafaxine</a> (the active, major metabolite of venlafaxine), <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="9506" href="/d/drug information/9506.html" rel="external">milnacipran</a>, and <a class="drug drug_general" data-topicid="90236" href="/d/drug information/90236.html" rel="external">levomilnacipran</a>. The pharmacology, administration, and side effects of SNRIs in the context of treating adults are discussed separately. (See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H14251861"><span class="h2">Indications and efficacy</span><span class="headingEndMark"> — </span>Although there is limited evidence from randomized studies to support the use of SNRIs as initial treatment of depressive disorders in children and adolescents, these medications appear to help patients who do not respond to initial treatment with a selective serotonin reuptake inhibitor (SSRI) or to a second trial with an alternate SSRI [<a href="#rid47">47</a>]. (See <a class="local">'Second-line'</a> above.)</p><p class="headingAnchor" id="H149956329"><span class="h3">Venlafaxine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">Venlafaxine</a> may possibly provide a small benefit for the initial treatment of youth with unipolar major depression [<a href="#rid48">48</a>]. A meta-analysis of two randomized trials (n = 334 children and adolescents with unipolar major depression, treated for eight weeks) compared venlafaxine extended release with placebo, and found that there was a trend for a greater rate of a modest response (reduction of baseline symptoms ≥35 percent) in patients treated with venlafaxine (risk ratio 1.2, 95% CI 1.0-1.4) [<a href="#rid5">5</a>].</p><p>In addition, <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> appears to be useful for depressed, pediatric patients who are unresponsive to initial treatment with SSRIs. The Treatment of Resistant Depression in Adolescents (TORDIA) trial enrolled 334 adolescents with unipolar major depression who did not respond to initial treatment with an SSRI, and randomly assigned them to switch to venlafaxine (150 to 225 mg per day), a different SSRI (<a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, or <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> 20 to 40 mg per day), venlafaxine plus cognitive-behavioral therapy (CBT), or a different SSRI plus CBT [<a href="#rid6">6</a>]. The study lasted 12 weeks, and found that the response (reduction of baseline symptoms ≥50 percent) in patients who received venlafaxine and patients who received a different SSRI was similar (48 and 47 percent). However, venlafaxine caused greater increases in diastolic blood pressure and pulse, and more skin problems such as itching and rash. In addition, follow-up 48 weeks after study intake found that patients who received SSRIs had a more rapid decline in self-reported depressive symptoms, including suicidal ideation, than patients treated with venlafaxine [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H4292142700"><span class="h3">Desvenlafaxine</span><span class="headingEndMark"> — </span>Randomized trials indicate that <a class="drug drug_general" data-topicid="8944" href="/d/drug information/8944.html" rel="external">desvenlafaxine</a> is not efficacious for pediatric depression:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, children and adolescents with unipolar major depression (n = 341) were randomly assigned to eight weeks of treatment with lower dose <a class="drug drug_general" data-topicid="8944" href="/d/drug information/8944.html" rel="external">desvenlafaxine</a> (20, 30, or 35 mg/day based upon baseline weight), higher dose desvenlafaxine (25, 35, or 50 mg/day), or placebo [<a href="#rid50">50</a>]. Improvement was comparable for the three groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, children and adolescents with unipolar major depression (n = 337) were randomly assigned to eight weeks of treatment with <a class="drug drug_general" data-topicid="8944" href="/d/drug information/8944.html" rel="external">desvenlafaxine</a> (25, 35, or 50 mg/day based upon baseline weight), <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> (20 mg/day), or placebo [<a href="#rid51">51</a>]. Response was comparable in patients who received desvenlafaxine or placebo (69 and 63 percent), whereas response occurred in more patients who received fluoxetine than placebo (78 versus 63 percent).</p><p></p><p class="headingAnchor" id="H4244888033"><span class="h3">Duloxetine</span><span class="headingEndMark"> — </span>Two randomized trials in children and adolescents with unipolar major depression found that the benefit of <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> and placebo was comparable [<a href="#rid52">52,53</a>]. However, the trials also found that <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> was not superior to placebo; given that multiple randomized trials have demonstrated that fluoxetine is efficacious for youth with major depression (see <a class="local">'Fluoxetine'</a> above), the two trials investigating duloxetine are failed, uninformative trials. Both trials were conducted by the same group of investigators, and the acute phase of treatment lasted 10 weeks:</p><p class="bulletIndent1"><span class="glyph">●</span>One trial randomly assigned youth with major depression (n = 463) to <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> 30 mg/day, duloxetine 60 mg/day, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> 20 mg/day, or placebo [<a href="#rid52">52</a>]. Response (reduction of baseline symptoms ≥50 percent) in each of the four groups was comparable (roughly 65 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second trial randomly assigned youth with major depression (n = 337) to <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> (flexible dose ranging from 60 to 120 mg/day), <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> (flexible dose ranging from 20 to 40 mg/day), or placebo [<a href="#rid53">53</a>]. Response in each group was comparable (approximately 65 percent of patients).</p><p></p><p>Case reports suggest that <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> may possibly be useful for comorbid depression and pain in pediatric patients [<a href="#rid54">54,55</a>].</p><p class="headingAnchor" id="H19515444"><span class="h1">TRICYCLIC ANTIDEPRESSANTS</span><span class="headingEndMark"> — </span>Tricyclic antidepressants include <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9283" href="/d/drug information/9283.html" rel="external">clomipramine</a>, <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">desipramine</a>, <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a>, <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a>, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="9832" href="/d/drug information/9832.html" rel="external">protriptyline</a>, and <a class="drug drug_general" data-topicid="10025" href="/d/drug information/10025.html" rel="external">trimipramine</a>. Although tricyclics are efficacious for adults with depression [<a href="#rid56">56,57</a>], studies in children and adolescents often fail to demonstrate any benefit [<a href="#rid14">14,58,59</a>].</p><p class="headingAnchor" id="H100967164"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Tricyclics are rarely indicated for depressed youth because of a frequent lack of efficacy, an unfavorable side effect profile, high lethality in overdose, and the availability of selective serotonin reuptake inhibitors (SSRIs). However, it is reasonable to administer tricyclics in patients who do not respond to multiple trials of SSRIs, serotonin-norepinephrine reuptake inhibitors, and other antidepressants [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H19515451"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>For pediatric patients with depressive disorders, the benefit of tricyclics is modest at best and may be limited to adolescents:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of nine randomized trials (454 children and adolescents) that compared tricyclics with placebo, recovery/response was comparable (relative risk 1.1, 95% CI 0.9-1.3) [<a href="#rid60">60</a>]. In addition, tricyclics caused more adverse effects, including dry mouth, orthostatic hypotension, tremor, and vertigo.</p><p></p><p class="bulletIndent1">However, a second analysis (13 trials, 533 patients) examined reduction of depression rating scale scores and found a clinically small advantage favoring tricyclics (<a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">desipramine</a>, <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a>, or <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>) over placebo; heterogeneity was moderate [<a href="#rid60">60</a>]. Subgroup analyses found that in adolescents (aged 13 to 18 years), tricyclics provided a clinically moderate benefit; by contrast, improvement of symptoms in children (aged 6 to 12 years) was comparable for tricyclics and placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 14 randomized trials (660 patients with depressive disorders, age ≤20 years) compared tricyclics with placebo, and found that there was a trend for a greater rate of response (reduction of baseline symptoms ≥50 percent) in patients treated with tricyclics (relative risk 1.15, 95% CI 0.98-1.34) [<a href="#rid14">14</a>]. Antidepressants provided one more response than placebo for every 15 patients treated with each regimen.</p><p></p><p>Tricyclics are less efficacious than SSRIs. (See <a class="local">'SSRIs as a class'</a> above.)</p><p class="headingAnchor" id="H19515458"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Tricyclic side effects in children and adolescents include dry mouth (which may lead to dental caries), orthostatic hypotension, tremor, and vertigo [<a href="#rid60">60</a>]. Tricyclics may also affect heart rate, blood pressure, and electrocardiogram parameters (eg, tachycardia, postural hypotension, hypertension, increased PR interval, QRS duration, and corrected QT interval [QTc]). The long-term clinical significance of these cardiac changes is not known [<a href="#rid58">58</a>]. Additional information about the adverse effects of tricyclics is discussed separately in the context of adults. (See  <a class="medical medical_review" href="/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H1739163"><span class="h3">Overdose</span><span class="headingEndMark"> — </span>Tricyclics are highly lethal in overdose. The toxicity is usually due to prolongation of the QT interval, leading to arrhythmias. Overdose of cyclic antidepressants can also cause anticholinergic toxicity and seizures. (See  <a class="medical medical_review" href="/d/html/295.html" rel="external">"Tricyclic antidepressant poisoning"</a>.)</p><p>We recommend that parents or caregivers assume responsibility for storing and administering tricyclics because of the risk of lethality in overdose, particularly for young patients and those at risk for suicide [<a href="#rid8">8,61</a>]. This is especially important during the acute phase of therapy and the first two to four months of remission.</p><p class="headingAnchor" id="H3395294"><span class="h1">OTHER ANTIDEPRESSANTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bupropion</strong> – Evidence for the effectiveness of <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> in pediatric patients with depression includes an eight week observational study in 24 adolescents with attention deficit hyperactivity disorder plus either unipolar major depression or persistent depressive disorder (dysthymia); depressive symptoms were much improved in 88 percent [<a href="#rid62">62</a>]. The study used the sustained release formulation of bupropion at doses up to 3 mg/kg twice per day, with each dose ≤150 mg; however, many clinicians prescribe 100 to 200 mg twice per day [<a href="#rid63">63</a>]. We typically prefer the extended release formulation of bupropion (150 to 450 mg once per day), which appears to have a more favorable pharmacokinetic profile (lower but more sustained serum concentrations) compared with the sustained release formulation [<a href="#rid64">64</a>]. In addition, improvement of depression with bupropion may be associated with higher serum concentrations of bupropion and its metabolites [<a href="#rid65">65</a>]. Seizures may occur with bupropion, especially in patients with eating disorders. (See  <a class="medical medical_review" href="/d/html/85816.html" rel="external">"Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vilazodone</strong> – Two randomized trials indicate that <a class="drug drug_general" data-topicid="16102" href="/d/drug information/16102.html" rel="external">vilazodone</a> is not efficacious for pediatric unipolar major depression:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an eight-week trial, adolescents aged 12 to 17 years old (n = 529) were randomized to fixed-dosed <a class="drug drug_general" data-topicid="16102" href="/d/drug information/16102.html" rel="external">vilazodone</a> (15 mg or 30 mg/day) or placebo; improvement for all three groups was comparable [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another eight-week trial, 473 youth aged 7 to 17 years old were randomly assigned to flexibly dosed <a class="drug drug_general" data-topicid="16102" href="/d/drug information/16102.html" rel="external">vilazodone</a> (15 to 30 mg/day), <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> (20 mg/day) or placebo. Improvement in all three groups was comparable [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mirtazapine</strong> – We generally avoid <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, based upon a pooled analysis of two trials that found mirtazapine (15 to 45 mg/day) provided no advantage over placebo [<a href="#rid5">5</a>]. Each trial lasted eight weeks and included youth (total n = 250) aged 8 to 18 years, who were diagnosed with unipolar major depression.</p><p></p><p class="headingAnchor" id="H26"><span class="h1">ADJUNCTIVE AGENTS</span><span class="headingEndMark"> — </span>Several drugs are available as augmentation for depressed children and adolescents with a partial response to antidepressants, but it is not known if adjunctive drugs are beneficial. Augmentation permits treatment to continue without interruption, thus avoiding a period of time with untreated symptoms and/or loss of a partial response. Agents that have been considered as add-on therapy include <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, second-generation antipsychotics, stimulants, and thyroid hormone, as well as <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> [<a href="#rid47">47,68</a>].</p><p>The use of adjunctive <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, second-generation antipsychotics, thyroid hormone, and <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> for depressed adults is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13506.html" rel="external">"Unipolar depression in adults: Treatment with lithium", section on 'Add-on lithium for treatment-resistant depression'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14688.html" rel="external">"Unipolar depression in adults: Treatment with second-generation antipsychotics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15722.html" rel="external">"Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Initial approach'</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">TREATMENT OPTIONS WITH LITTLE OR NO BENEFIT</span></p><p class="headingAnchor" id="H28"><span class="h2">Omega-3 fatty acids</span><span class="headingEndMark"> — </span>We typically do not use omega-3 fatty acids (n-3 polyunsaturated fatty acids) for acute pediatric depression, because there are no high-quality studies that have established that these medications are efficacious:</p><p class="bulletIndent1"><span class="glyph">●</span>A 16-week trial randomly assigned 28 children (aged 6 to 12 years) with unipolar major depression to receive omega-3 fatty acids (approximately 400 mg of eicosapentaenoic acid and 200 mg docosahexaenoic acid) or placebo [<a href="#rid69">69</a>]. Among the 20 children who completed at least one month of the study, improvement was greater with omega-3 fatty acids than placebo. In addition, there were no clinically important side effects. However, these results are not compelling, due to the small sample size as well as the analysis, which included only study completers rather than all patients who were randomized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Different meta-analyses of randomized trials in adults have found conflicting results regarding the benefit of omega-3 fatty acids compared with placebo. Heterogeneity across studies is typically substantial and publication bias may account for the benefits observed in some meta-analyses. (See  <a class="medical medical_review" href="/d/html/90155.html" rel="external">"Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Omega-3 fatty acids'</a>.)</p><p></p><p class="headingAnchor" id="H29"><span class="h2">St. John's wort</span><span class="headingEndMark"> — </span>We do not suggest St. John's wort (<em>Hypericum</em> <em>perforatum</em>) for treating pediatric depressive disorders. Studies of St. John's wort in adults with mild to moderate depressive disorders have yielded inconsistent results, and no high-quality studies have been performed in children and adolescents. In addition, pharmacotherapy is not usually recommended for children and adolescents with mild depression. The efficacy of St. John’s wort for depressed adults is discussed separately. (See  <a class="medical medical_review" href="/d/html/1391.html" rel="external">"Clinical use of St. John's wort", section on 'Depression'</a>.)</p><p>Additional information about St. John's wort is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2Fhealth%2Fst-johns-wort&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fz3wh0Bqb8lzeSfvlLTqiX7TEieJfgwTcOp5FWgweNFyUGHi0UhbZlJMTCOpTFXlHw%3D%3D&amp;TOPIC_ID=1227" target="_blank">the website</a> of the National Center for Complementary and Alternative Medicine, a branch of the United States National Institutes of Health.</p><p class="headingAnchor" id="H520742607"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H1071614"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/140703.html" rel="external">"Patient education: Depression in children and teens (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4867.html" rel="external">"Patient education: Depression in children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4870.html" rel="external">"Patient education: Depression treatment options for children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p>Additional sources of information about unipolar major depression and treatment that is intended for patients and families is discussed separately. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression", section on 'Education and resources'</a>.)</p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for and education about pharmacotherapy</strong> – Pharmacotherapy is reserved for children and adolescents who meet criteria for a depressive disorder such as moderate to severe major depression  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 2</a>), persistent depressive disorder (dysthymia)  (<a class="graphic graphic_table graphicRef91114" href="/d/graphic/91114.html" rel="external">table 8</a>), or depressive symptoms with functional impairment, and who can be monitored by clinicians and families. Prior to starting antidepressants, it is incumbent upon clinicians to educate patients and families about depression, and discuss the benefits and side effects of medications  (<a class="graphic graphic_table graphicRef77780" href="/d/graphic/77780.html" rel="external">table 9</a>), the potential for increased suicidal ideation and behavior  (<a class="graphic graphic_table graphicRef54498" href="/d/graphic/54498.html" rel="external">table 10</a>), other safety risks (eg, cardiac events), and the risks of untreated depression. (See  <a class="medical medical_review" href="/d/html/88735.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: General principles", section on 'Prescribing pharmacotherapy'</a> and  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a> and <a class="local">'Adverse side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line pharmacotherapy</strong> – For children and adolescents with moderate to severe depressive disorders who are treated with pharmacotherapy, we suggest <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> as first-line treatment, rather than other antidepressants (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'First-line'</a> above and <a class="local">'Fluoxetine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line pharmacotherapy</strong> – For depressed pediatric patients who do not respond to initial treatment with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, we suggest switching to <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, rather than other antidepressants (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). However, reasonable alternatives include <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>. We typically do not use <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> for pediatric depression because of its lack of demonstrated efficacy. (See <a class="local">'Second-line'</a> above and <a class="local">'Other specific SSRIs'</a> above and <a class="local">'Indications and efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Third-line pharmacotherapy</strong> – Antidepressant options for depressed youth who do not respond to or tolerate selective serotonin reuptake inhibitors or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> include <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> and <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>; tricyclic antidepressants are rarely used. (See <a class="local">'Third-line'</a> above and <a class="local">'Tricyclic antidepressants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuation and maintenance pharmacotherapy</strong> – For children and adolescents who are treated acutely with antidepressants and remit, we recommend that the same regimen be continued for at least six months, rather than discontinuing pharmacotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Continuation and maintenance treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ambrosini PJ. A review of pharmacotherapy of major depression in children and adolescents. Psychiatr Serv 2000; 51:627.</a></li><li><a class="nounderline abstract_t">Brent DA, Gibbons RD, Wilkinson P, Dubicka B. Antidepressants in paediatric depression: do not look back in anger but around in awareness. BJPsych Bull 2018; 42:1.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:572.</a></li><li><a class="nounderline abstract_t">Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev 2021; 5:CD013674.</a></li><li><a class="nounderline abstract_t">Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD004851.</a></li><li><a class="nounderline abstract_t">Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.</a></li><li><a class="nounderline abstract_t">Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351:h4320.</a></li><li><a class="nounderline abstract_t">Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Rush AJ, Weinberg WA, et al. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998; 7:32.</a></li><li><a class="nounderline abstract_t">Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 1996; 35:1575.</a></li><li><a class="nounderline abstract_t">Linden M, Gothe H, Dittmann RW, Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 2000; 20:523.</a></li><li><a class="nounderline abstract_t">Cox GR, Fisher CA, De Silva S, et al. Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD007504.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459.</a></li><li><a class="nounderline abstract_t">Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008; 193:10.</a></li><li><a class="nounderline abstract_t">Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683.</a></li><li><a class="nounderline abstract_t">Ignaszewski MJ, Waslick B. Update on Randomized Placebo-Controlled Trials in the Past Decade for Treatment of Major Depressive Disorder in Child and Adolescent Patients: A Systematic Review. J Child Adolesc Psychopharmacol 2018; 28:668.</a></li><li><a class="nounderline abstract_t">Bridge JA, Birmaher B, Iyengar S, et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166:42.</a></li><li><a class="nounderline abstract_t">Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016; 388:881.</a></li><li class="breakAll">The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Washington, D.C. 2009.</li><li><a class="nounderline abstract_t">Qin B, Zhang Y, Zhou X, et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. Clin Ther 2014; 36:1087.</a></li><li><a class="nounderline abstract_t">Varigonda AL, Jakubovski E, Taylor MJ, et al. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:557.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54:1031.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41:1205.</a></li><li><a class="nounderline abstract_t">March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.</a></li><li><a class="nounderline abstract_t">Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14:791.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43:1397.</a></li><li><a class="nounderline abstract_t">Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335:142.</a></li><li><a class="nounderline abstract_t">Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290:1033.</a></li><li><a class="nounderline abstract_t">Wagner KD, Jonas J, Findling RL, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006; 45:280.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009; 48:721.</a></li><li><a class="nounderline abstract_t">Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161:1079.</a></li><li><a class="nounderline abstract_t">von Knorring AL, Olsson GI, Thomsen PH, et al. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006; 26:311.</a></li><li class="breakAll">FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).</li><li class="breakAll">FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).</li><li><a class="nounderline abstract_t">Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001; 344:1279.</a></li><li><a class="nounderline abstract_t">Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40:222.</a></li><li><a class="nounderline abstract_t">Richmond TK, Rosen DS. The treatment of adolescent depression in the era of the black box warning. Curr Opin Pediatr 2005; 17:466.</a></li><li class="breakAll">US Food and Drug Administration. Background on suicidality associated with antidepressant drug treatment. Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-04-Tab02-Laughren-Jan5.pdf (Accessed on March 24, 2008).</li><li><a class="nounderline abstract_t">Locher C, Koechlin H, Zion SR, et al. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. JAMA Psychiatry 2017; 74:1011.</a></li><li><a class="nounderline abstract_t">Dobson ET, Strawn JR. Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation. J Child Adolesc Psychopharmacol 2016; 26:686.</a></li><li><a class="nounderline abstract_t">Strawn JR, Dobson ET, Giles LL. Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety. Curr Probl Pediatr Adolesc Health Care 2017; 47:3.</a></li><li><a class="nounderline abstract_t">Walkup JT. Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies. Am J Psychiatry 2017; 174:430.</a></li><li><a class="nounderline abstract_t">Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006; 16:131.</a></li><li><a class="nounderline abstract_t">Molero Y, Lichtenstein P, Zetterqvist J, et al. Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study. PLoS Med 2015; 12:e1001875.</a></li><li><a class="nounderline abstract_t">Luft MJ, Lamy M, DelBello MP, et al. Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management. Curr Probl Pediatr Adolesc Health Care 2018; 48:50.</a></li><li><a class="nounderline abstract_t">Czaja AS, Valuck RJ, Anderson HD. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. Pharmacoepidemiol Drug Saf 2013; 22:607.</a></li><li><a class="nounderline abstract_t">Hughes CW, Emslie GJ, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1442.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Findling RL, Yeung PP, et al. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007; 46:479.</a></li><li><a class="nounderline abstract_t">Vitiello B, Emslie G, Clarke G, et al. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry 2011; 72:388.</a></li><li><a class="nounderline abstract_t">Atkinson S, Lubaczewski S, Ramaker S, et al. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol 2018; 28:55.</a></li><li><a class="nounderline abstract_t">Weihs KL, Murphy W, Abbas R, et al. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol 2018; 28:36.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Prakash A, Zhang Q, et al. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24:170.</a></li><li><a class="nounderline abstract_t">Atkinson SD, Prakash A, Zhang Q, et al. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24:180.</a></li><li><a class="nounderline abstract_t">Meighen KG. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol 2007; 17:121.</a></li><li><a class="nounderline abstract_t">Desarkar P, Das A, Sinha VK. Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry 2006; 15:496.</a></li><li><a class="nounderline abstract_t">von Wolff A, Hölzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013; 144:7.</a></li><li><a class="nounderline abstract_t">Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3:449.</a></li><li><a class="nounderline abstract_t">Geller B, Reising D, Leonard HL, et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38:513.</a></li><li><a class="nounderline abstract_t">Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; :CD002317.</a></li><li><a class="nounderline abstract_t">Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2013; :CD002317.</a></li><li><a class="nounderline abstract_t">White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008; 4:238.</a></li><li><a class="nounderline abstract_t">Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001; 40:307.</a></li><li><a class="nounderline abstract_t">Daviss WB, Perel JM, Rudolph GR, et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry 2005; 44:349.</a></li><li><a class="nounderline abstract_t">Daviss WB, Perel JM, Birmaher B, et al. Steady-state clinical pharmacokinetics of bupropion extended-release in youths. J Am Acad Child Adolesc Psychiatry 2006; 45:1503.</a></li><li><a class="nounderline abstract_t">Daviss WB, Perel JM, Brent DA, et al. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study. Ther Drug Monit 2006; 28:190.</a></li><li><a class="nounderline abstract_t">Durgam S, Chen C, Migliore R, et al. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder. Paediatr Drugs 2018; 20:353.</a></li><li><a class="nounderline abstract_t">Findling RL, McCusker E, Strawn JR. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up. J Child Adolesc Psychopharmacol 2020; 30:355.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Mayes T, Porta G, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry 2010; 167:782.</a></li><li><a class="nounderline abstract_t">Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163:1098.</a></li></ol></div><div id="topicVersionRevision">Topic 1227 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783181" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A review of pharmacotherapy of major depression in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29388523" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antidepressants in paediatric depression: do not look back in anger but around in awareness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393205" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34029378" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New generation antidepressants for depression in children and adolescents: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152227" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Newer generation antidepressants for depressive disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18314433" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26376805" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18049300" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9592630" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fluoxetine in child and adolescent depression: acute and maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8973063" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Childhood and adolescent depression: a review of the past 10 years. Part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001236" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Early termination of antidepressant drug treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152246" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281410" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18700212" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of antidepressants in juvenile depression: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440145" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30063169" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Update on Randomized Placebo-Controlled Trials in the Past Decade for Treatment of Major Depressive Disorder in Child and Adolescent Patients: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047322" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27289172" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27289172" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24998011" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088660" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366660" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364842" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15315995" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2293257" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502599" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556431" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12941675" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540812" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465881" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15169696" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702897" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702897" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702897" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323729" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11211371" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012257" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The treatment of adolescent depression in the era of the black box warning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012257" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The treatment of adolescent depression in the era of the black box warning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854296" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27027330" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28043839" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28253735" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553534" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372359" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29358037" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23456956" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10560232" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420682" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208583" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29185786" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189044" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815533" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813026" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17343560" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732464" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Duloxetine for childhood depression with pain and dissociative symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22963896" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189062" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10230182" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Critical review of tricyclic antidepressant use in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076448" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tricyclic drugs for depression in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23780719" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tricyclic drugs for depression in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19031375" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11288772" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15782082" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Steady-state pharmacokinetics of bupropion SR in juvenile patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135996" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Steady-state clinical pharmacokinetics of bupropion extended-release in youths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628130" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29633166" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32460523" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478877" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16741212" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Omega-3 treatment of childhood depression: a controlled, double-blind pilot study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
